• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Is neutrophil-to-lymphocyte ratio and C-reactive protein the prognostic role in metastatic colorectal cancer using regorafenib?

作者信息

Chen Xinyang, Li Hancong, Feng Qingbo

机构信息

West China School of Medicine, West China Hospital, Sichuan University, Chengdu, China.

Department of Liver Surgery and Liver Transplantation Centre, West China Hospital, Sichuan University, Chengdu, China.

出版信息

J Gastrointest Oncol. 2023 Feb 28;14(1):472-473. doi: 10.21037/jgo-22-1128. Epub 2023 Jan 16.

DOI:10.21037/jgo-22-1128
PMID:36915434
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10007952/
Abstract
摘要

相似文献

1
Is neutrophil-to-lymphocyte ratio and C-reactive protein the prognostic role in metastatic colorectal cancer using regorafenib?中性粒细胞与淋巴细胞比值和C反应蛋白在使用瑞戈非尼治疗转移性结直肠癌中是否具有预后作用？
J Gastrointest Oncol. 2023 Feb 28;14(1):472-473. doi: 10.21037/jgo-22-1128. Epub 2023 Jan 16.
2
Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management.接受瑞戈非尼治疗的经治结直肠癌患者的预后临床因素：对临床管理的意义
Oncotarget. 2015 Oct 20;6(32):33982-92. doi: 10.18632/oncotarget.5053.
3
Lymphocyte-to-C-Reactive Protein Ratio Is the Most Sensitive Inflammation-Based Prognostic Score in Patients With Unresectable Metastatic Colorectal Cancer.淋巴细胞与 C 反应蛋白比值是不可切除转移性结直肠癌患者最敏感的基于炎症的预后评分。
Dis Colon Rectum. 2021 Nov 1;64(11):1331-1341. doi: 10.1097/DCR.0000000000002059.
4
Could the Inflammatory Prognostic Index Predict the Efficacy of Regorafenib in Patients with Metastatic Colorectal Cancer?炎症预后指数能否预测转移性结直肠癌患者regorafenib 的疗效？
J Gastrointest Cancer. 2022 Mar;53(1):45-51. doi: 10.1007/s12029-021-00642-w. Epub 2021 Apr 21.
5
Development and Validation of a Novel Serum Prognostic Marker for Patients with Metastatic Colorectal Cancer on Regorafenib Treatment.一种用于接受瑞戈非尼治疗的转移性结直肠癌患者的新型血清预后标志物的开发与验证
Cancers (Basel). 2021 Oct 11;13(20):5080. doi: 10.3390/cancers13205080.
6
The prognostic role of polypharmacy in metastatic colorectal cancer patients treated with regorafenib.多药联合治疗在接受瑞戈非尼治疗的转移性结直肠癌患者中的预后作用。
Future Oncol. 2022 Mar;18(9):1067-1076. doi: 10.2217/fon-2021-1182. Epub 2022 Feb 3.
7
PD-L1 Expression on Circulating Tumour Cells May Be Predictive of Response to Regorafenib in Patients Diagnosed with Chemorefractory Metastatic Colorectal Cancer.循环肿瘤细胞上的 PD-L1 表达可能与化疗耐药转移性结直肠癌患者对regorafenib 的反应相关。
Int J Mol Sci. 2020 Sep 20;21(18):6907. doi: 10.3390/ijms21186907.
8
A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis.regorafenib 与 TAS-102 治疗转移性结直肠癌的比较：系统评价和网络荟萃分析。
Clin Colorectal Cancer. 2018 Jun;17(2):113-120. doi: 10.1016/j.clcc.2017.10.016. Epub 2017 Nov 22.
9
Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study.评估regorafenib 或 trifluridine/tipiracil 用于转移性结直肠癌患者的生存获益的预后评分：REGOTAS 研究的探索性分析。
Int J Clin Oncol. 2020 Apr;25(4):614-621. doi: 10.1007/s10147-019-01600-0. Epub 2019 Dec 14.
10
Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study.真实世界研究：regorafenib 联合免疫检查点抑制剂治疗晚期或转移性微卫星稳定结直肠癌患者的疗效：一项多中心研究。
Cancer Immunol Immunother. 2022 Jun;71(6):1443-1451. doi: 10.1007/s00262-021-03083-3. Epub 2021 Oct 24.

引用本文的文献

1
Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: a retrospective cohort study.瑞戈非尼治疗转移性结直肠癌的疗效与安全性：一项回顾性队列研究
J Gastrointest Oncol. 2024 Jun 30;15(3):987-1001. doi: 10.21037/jgo-24-180. Epub 2024 Jun 18.

本文引用的文献

1
The prognostic role of neutrophil-to-lymphocyte ratio and C-reactive protein in metastatic colorectal cancer using regorafenib: a systematic review and meta-analysis.中性粒细胞与淋巴细胞比值及C反应蛋白在转移性结直肠癌使用瑞戈非尼治疗中的预后作用：一项系统评价和荟萃分析
J Gastrointest Oncol. 2022 Aug;13(4):1772-1781. doi: 10.21037/jgo-22-683.
2
Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study.真实世界研究：regorafenib 联合免疫检查点抑制剂治疗晚期或转移性微卫星稳定结直肠癌患者的疗效：一项多中心研究。
Cancer Immunol Immunother. 2022 Jun;71(6):1443-1451. doi: 10.1007/s00262-021-03083-3. Epub 2021 Oct 24.
3
Association of albumin-bilirubin score in patients with colorectal cancer receiving later-line chemotherapy with regorafenib.白蛋白-胆红素评分与接受瑞戈非尼二线化疗的结直肠癌患者的相关性。
Int J Clin Oncol. 2021 Jul;26(7):1257-1263. doi: 10.1007/s10147-021-01910-2. Epub 2021 Apr 11.
4
Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS).瑞戈非尼与曲氟尿苷/盐酸替匹嘧啶交叉给药对转移性结直肠癌患者的生存获益：日本结直肠癌学会多中心观察性研究（REGOTAS）的探索性分析
Front Oncol. 2021 Mar 8;11:576036. doi: 10.3389/fonc.2021.576036. eCollection 2021.
5
Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study.评估regorafenib 或 trifluridine/tipiracil 用于转移性结直肠癌患者的生存获益的预后评分：REGOTAS 研究的探索性分析。
Int J Clin Oncol. 2020 Apr;25(4):614-621. doi: 10.1007/s10147-019-01600-0. Epub 2019 Dec 14.
6
Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management.接受瑞戈非尼治疗的经治结直肠癌患者的预后临床因素：对临床管理的意义
Oncotarget. 2015 Oct 20;6(32):33982-92. doi: 10.18632/oncotarget.5053.